Biodexa Pharmaceuticals PLC faces Nasdaq delisting due to low stock price.

From GlobeNewswire: 2024-08-30 16:30:00

Biodexa Pharmaceuticals PLC received a Nasdaq delisting determination due to securities trading below $1.00 for 30 consecutive days. The company plans to appeal to avoid suspension/delisting. Biodexa is a clinical stage biopharmaceutical company developing innovative products for diseases with unmet medical needs. Lead programs include eRapa for Familial Adenomatous Polyposis and Tolimidone for type 1 diabetes. MTX110 is being studied in rare brain cancer indications. Biodexa is supported by proprietary drug delivery technologies. Forward-looking statements caution about potential risks and uncertainties. For more information, visit www.biodexapharma.com.



Read more at GlobeNewswire: Receipt of Nasdaq Delisting Determination